Heart Transplant or Implant of Heart Assist System with MCC DRG Reimbursement

Summary & Overview

Heart Transplant or Implant of Heart Assist System with MCC: Inpatient Reimbursement Overview

DRG 001 addresses heart transplant or implantation of a heart assist system with Major Complication or Comorbidity, encompassing the most complex cardiac surgical admissions. This Diagnosis-Related Group is critical for inpatient reimbursement because it represents high resource utilization and significantly impacts Medicare payment determinations.

Heart TransplantDRG Heart Transplant or Implant of Heart Assist System with MCCDRG 001Diagnosis-Related GroupInpatient ReimbursementMedicareCardiac SurgeryMechanical Circulatory SupportCardiologyTransplantation

DRG 001 Overview

DRG 001 covers inpatient admissions for heart transplant or implantation of a heart assist system with Major Complication or Comorbidity. This Diagnosis-Related Group captures the highest complexity cardiac surgical cases that drive substantial resource use, including postoperative intensive care and prolonged hospitalization. It matters for Medicare payment because it represents one of the most resource-intensive Diagnosis-Related Groups, influencing base payment, outlier considerations, and hospital financial planning. Precise coding of diagnoses and procedures determines assignment to this Diagnosis-Related Group and consequent reimbursement tiers.

National Payment Rates

Across national payers the observed rate range spans roughly $170K to $990K, with Anthem and Blue Cross Blue Shield showing the highest maximums. The widest spread between a payer’s minimum and maximum is seen with Anthem (up to $990K). See the table and chart below for payer-specific quartiles and medians for Anthem, Aetna, Cigna, and BCBS.

Mean Rates by Payer — National — DRG 001

The CMS 2023 dataset reflects national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($332.9k), average submitted covered charges ($1.5m), average Medicare payment ($281.5k), and total discharges (2.0k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

In Alaska for DRG 001, mean rates across payers range from $440K to $490K, with Cigna at the top end and Anthem and Blue Cross Blue Shield at the low end. This represents a narrow state-level spread and a modest elevation above some national averages at the top payer. See the table and chart below for payer-specific distribution and percentile detail.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska at a mean of $490K, while Anthem and Blue Cross Blue Shield are tied as the lowest payers at a mean of $440K.
The statewide mean range spans from $440K to $490K, a relatively tight band compared with national variability; Alaska’s highest mean ($490K) modestly exceeds the national mean benchmarks shown but the lowest means ($440K) align with national medians, indicating limited upside in the market.

Clinical Trials

Perioperative management and device optimization trials: These studies focus on immediate intraoperative and early postoperative strategies for heart transplant recipients and patients receiving durable or temporary mechanical circulatory support devices, investigating protocols for anticoagulation timing, hemodynamic support algorithms, infection prophylaxis, and strategies to minimize right ventricular failure after device implantation. The patient population includes adults undergoing orthotopic heart transplantation or implantation of left ventricular assist devices (LVADs) or temporary extracorporeal support, often with multiple organ dysfunction or high surgical risk. Results are relevant to providers for improving survival and complication rates in the index hospitalization and to payers because optimized perioperative protocols can reduce intensive care length of stay, device-related complications, and readmissions that drive high costs under this DRG.
Comparative effectiveness studies of long-term support versus transplantation candidacy: These trials compare outcomes between patients who proceed to durable mechanical circulatory support as destination therapy or bridge-to-transplant versus those listed for transplantation, assessing survival, quality of life, functional status, and resource utilization over months to years. The studies enroll advanced heart failure patients who meet criteria for transplantation or durable assist devices, including those with comorbidities that influence candidacy decisions. Findings inform clinicians and transplant programs about patient selection and timing decisions, and inform payers and hospitals about downstream costs and expected trajectories linked to an index hospitalization coded under this DRG.
Post-discharge outcomes and readmission reduction trials: These pragmatic trials evaluate care-transition interventions such as structured discharge planning, remote hemodynamic monitoring, telehealth follow-up, and outpatient anticoagulation or infection surveillance programs aimed at reducing 30- and 90-day readmissions, device-related complications, and graft rejection episodes. The participant pool consists of recent heart transplant recipients and patients discharged with an implanted assist device, including those with varying social support and frailty levels that impact post-acute care needs. This research is critical for providers to identify effective outpatient management pathways that improve long-term outcomes and for payers to understand interventions that can lower costly readmissions and post-acute care expenditures associated with this DRG.

Related Codes

007-LUNG-TRANSPLANT

Lung Transplant: Inpatient Reimbursement Overview

005-LIVER-TRANSPLANT-WITH-MCC-OR-INTESTINAL-TRANSPLANT

Liver Transplant with MCC or Intestinal Transplant: Inpatient Reimbursement Overview

010-PANCREAS-TRANSPLANT

Pancreas Transplant: Inpatient Reimbursement Overview

011-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-MCC

Tracheostomy/Laryngectomy with MCC: Inpatient Reimbursement Overview

002-HEART-TRANSPLANT-OR-IMPLANT-OF-HEART-ASSIST-SYSTEM-WITHOUT-MCC

Heart Transplant or Implant of Heart Assist System without MCC: Inpatient Reimbursement Overview

017-AUTOLOGOUS-BONE-MARROW-TRANSPLANT-WITHOUT-CC-MCC

Autologous Bone Marrow Transplant without CC/MCC: Inpatient Reimbursement Overview

004-TRACHEOSTOMY-WITH-MV-96-HOURS-OR-PRINCIPAL-DIAGNOSIS-EXCEPT-FACE-MOUTH-AND-NECK-WITHOUT-MAJOR-O-R-PROCEDURES

Tracheostomy with Mechanical Ventilation >96 Hours: Inpatient Reimbursement Overview

019-SIMULTANEOUS-PANCREAS-AND-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS

Simultaneous Pancreas and Kidney Transplant with Hemodialysis: Inpatient Reimbursement Overview

008-SIMULTANEOUS-PANCREAS-AND-KIDNEY-TRANSPLANT

Simultaneous Pancreas and Kidney Transplant: Inpatient Reimbursement Overview

012-TRACHEOSTOMY-FOR-FACE-MOUTH-AND-NECK-DIAGNOSES-OR-LARYNGECTOMY-WITH-CC

Tracheostomy and Laryngectomy with CC: Inpatient Reimbursement Overview

Showing 1–10 of 16

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$330K	$1.5M	$280K	2K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 001

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska at a mean of $490K, while Anthem and Blue Cross Blue Shield are tied as the lowest payers at a mean of $440K.
The statewide mean range spans from $440K to $490K, a relatively tight band compared with national variability; Alaska’s highest mean ($490K) modestly exceeds the national mean benchmarks shown but the lowest means ($440K) align with national medians, indicating limited upside in the market.

Clinical Trials

Perioperative management and device optimization trials: These studies focus on immediate intraoperative and early postoperative strategies for heart transplant recipients and patients receiving durable or temporary mechanical circulatory support devices, investigating protocols for anticoagulation timing, hemodynamic support algorithms, infection prophylaxis, and strategies to minimize right ventricular failure after device implantation. The patient population includes adults undergoing orthotopic heart transplantation or implantation of left ventricular assist devices (LVADs) or temporary extracorporeal support, often with multiple organ dysfunction or high surgical risk. Results are relevant to providers for improving survival and complication rates in the index hospitalization and to payers because optimized perioperative protocols can reduce intensive care length of stay, device-related complications, and readmissions that drive high costs under this DRG.
Comparative effectiveness studies of long-term support versus transplantation candidacy: These trials compare outcomes between patients who proceed to durable mechanical circulatory support as destination therapy or bridge-to-transplant versus those listed for transplantation, assessing survival, quality of life, functional status, and resource utilization over months to years. The studies enroll advanced heart failure patients who meet criteria for transplantation or durable assist devices, including those with comorbidities that influence candidacy decisions. Findings inform clinicians and transplant programs about patient selection and timing decisions, and inform payers and hospitals about downstream costs and expected trajectories linked to an index hospitalization coded under this DRG.
Post-discharge outcomes and readmission reduction trials: These pragmatic trials evaluate care-transition interventions such as structured discharge planning, remote hemodynamic monitoring, telehealth follow-up, and outpatient anticoagulation or infection surveillance programs aimed at reducing 30- and 90-day readmissions, device-related complications, and graft rejection episodes. The participant pool consists of recent heart transplant recipients and patients discharged with an implanted assist device, including those with varying social support and frailty levels that impact post-acute care needs. This research is critical for providers to identify effective outpatient management pathways that improve long-term outcomes and for payers to understand interventions that can lower costly readmissions and post-acute care expenditures associated with this DRG.